Market Newsdesk

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the 32nd Annual Piper Sandler Virtual Healthcare Conference taking place between December 1-3, 2020, as well as in a panel discussion at the 3rd Annual Evercore ISI HealthCONx Conference, which is also being held from December 1-3, 2020.

A webcast of the Piper Sandler fireside chat will be available on the Piper Sandler conference site from November 23rd to December 3rd. In addition, this webcast will also be available on the NeuBase website, www.neubasetherapeutics.com, for 90 days following the recording of the presentation.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576

NeuBase Media Contact:

Cait Williamson, Ph.D.
LifeSci Public Relations
[email protected]
OP: (646) 751-4366

LONDON, Nov. 23, 2020 (GLOBE NEWSWIRE) — SNOMED International has released a series of videos that demonstrate the value that a healthcare system is deriving from implementing and using SNOMED CT, the world’s most comprehensive clinical terminology.

The first chapter of the SNOMED CT Value Series, which focuses on New Zealand’s Canterbury District Health Board (CDHB), highlights the advances the organization has made in realizing its vision of a connected, integrated system that supports the country’s Healthy Ageing strategy and enables it to better serve its population. Acting Executive Director Planning, Funding and Decision Support, Ralph La Salle offers that “an integrated health system is essential for the health outcomes of the Canterbury population and quality data with thorough analysis leads to shared clinical insights and new ways of working collectively to optimise this integration.”

Carolyn Gullery, who at the time of filming was the Executive Director, Planning, Funding and Decision Support for the CDHB, said New Zealand’s commitment to becoming a SNOMED International Member in 2007 was the beginning of a positive change for a healthcare system that was, like so many others across the globe, under extreme financial and performance-related pressure. She explains that in 2007, while its primary care system was thriving, its hospital system was struggling. Canterbury needed a better picture of its current situation and a way to predict the future needs of its 578,000 residents.

Harnessing the power of data analytics

Key to that goal, she noted, was the ability to use data and analytics to understand why people were ending up in the health system, who they were and how to intervene more effectively to reduce the demand on the system and provide better care for patients. By using SNOMED CT as part of its core infrastructure, and its Healthcare Analytics Solution (HCAS), a software tool that applies natural language processing to the unstructured text-based data in a clinical record, the health boards were able to code their existing data to SNOMED CT and then demonstrate to clinicians the power of using those codes to analyze that data. It is estimated that approximately 80 percent of health data is unstructured, and can represent text, photos, X-rays, voice/video recordings, slides and emails, among other types of health data.

By building a series of systems that act as an integrated health platform, CDHB managed to use the same number of beds in 2019 as it did in 2007 for a population that over 12 years had grown by 80,000. Canterbury representatives also observed a 30 percent lower emergency department use and a 30 percent lower acute medical admission rate than the national average, meaning New Zealanders are less likely to end up in the hospital in Canterbury than in any other part of the country.

R
educing manual labor for clinicians

According to Dr. Nigel Gilchrist, a Canterbury physician, the organization had also struggled to identify vertebral spine fractures and identify patients who may not have received care for those fractures. By using SNOMED CT to search 13,000 X-ray reports as part of a pilot project involving West Coast DHB patients, the organization found that one-third of relevant patients had been treated, another third had not, and the remaining third had been misclassified.

“We now identify over 200 new vertebral fractures every month,” he explained. “SNOMED CT has enabled us to identify specific case mixes that would otherwise take someone a long time to do manually.” In fact, the organization saved more than a year of a clinician’s time.

Interoperability across platforms

Another benefit of using SNOMED CT is its interoperability across the healthcare district’s best-of-breed applications. “We need to be sure we’re speaking the same language when we use data, and if we move it around, it’s got to mean the same thing in one place as in another,” said Dr. Saxon Connor, a Canterbury physician.

Other Canterbury clinicians say they are most excited by SNOMED CT’s ability to help two different clinical tools – an electronic medical record system and a pathways tool – talk to each other via a SNOMED CT code linked to diagnoses, and by the ability to search for pathways and find hierarchies.

“In the past, we had to go through our pathways manually and put keywords on them so people could find them, and with SNOMED we get all those synonyms for free,” said Kieran Holland, Clinical Lead for New Zealand’s HealthPathways Programme, an online clinical guidance tool. “It has improved the user search experience.”

SNOMED CT: a piece of the digital health ecosystem as CDHB realizes multiple benefits

• 30 percent lower emergency department use than the national average
• 30 percent lower acute medical admission rate than the national average
• Held 2019 bed use to same numbers as in 2007 while serving a population that had grown by 80,000
• Identified vertebral fracture patients who had not received care or whose cases had been misclassified
• Saved a year of clinician time by automating previously manual processes
• Interoperable across best-of-breed system
• Ability to link clinical tools via a SNOMED code
• Ability to search for pathways and hierarchies and improved user search experience

There is more energy than ever in rolling out SNOMED CT as a key clinical information standard for an equitable New Zealand health and disability system, one that is data-driven and digitally enabled and SNOMED International’s CEO, Don Sweete, recognizes the dedication of New Zealand’s implementation efforts. “Canterbury is a great example of the breadth of maturity that SNOMED CT offers from data coding, data analysis, and ultimately the ability to apply artificial intelligence to already structured SNOMED CT data. It’s an end to end example of the benefit of SNOMED CT.”

New Zealand’s focus over the next few years is on primary and community care, where users are migrating their systems from Read Codes to SNOMED CT as they introduce new models of care and supporting software.

Watch the Value Series to learn more about SNOMED CT and New Zealand, a founding SNOMED International Member represented by the Ministry of Health Manatū Hauora.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product.  We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms.  This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community.  SNOMED International is the trading name of the International Health Terminology Standards Development Organisation. Learn More…

Kelly Kuru
Chief Communications Officer
SNOMED International
[email protected]

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) — APPlife Digital Solutions, Inc. (OTCQB: ALDS) (“APPlife”, the Company”), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions announced today that they have entered into a non-binding term sheet to acquire a company that provides plant-based food distribution and an end-to-end, technology-driven supply chain management system dedicated to improving connectivity, and driving efficiencies, transparency and waste reduction throughout the food industry.

The terms of the acquisition and the target’s name will be disclosed upon the execution of a definitive agreement, which is anticipated to be completed by December 20^th, 2020.

The target company’s plant-based food distribution division has posted revenue of approximately $1 million for the trailing 12 months and is expected to produce $3 million in revenue by the end of 2021 and $5 million in revenue by mid-2022. The supply chain SaaS (software as a service) technology division is forecasted to achieve $1 million in revenue in 2021 and $10 million in revenue by the end of 2022.

“We chose the target based on the revenue, the business model and a strong and driven management team that will stay on and continue to operate and grow the business as a subsidiary of APPlife,” stated Matt Reid CEO of APPlife. “We are looking forward to a very exciting 2021 and we will continue to provide our shareholders and investors with updates on this transaction as well as other corporate developments as we are able,” added Reid.

ABOUT APPLIFE DIGITAL SOLUTION
S
, INC.

APPlife Digital Solutions Inc., with offices in San Francisco CA. and Shanghai China, is a business incubator and portfolio manager that uses digital technology to create and invests in e-commerce and cloud-based solutions. The Company invests in and creates solutions for work, home life, recreation and research that makes users more productive and more efficient, whether at work, home or traveling the world. APPlife’s cloud-based businesses are designed to provide easy-to-use life solutions, often to address everyday issues and needs. They include a wide array of topics and needed services to cover the full marketplace across the spectrum. For more information visit www.applifedigital.com.

Current APPlife Digital Solutions, Inc. e-commerce solutions:

Rooster Essentia
ls – The “Go To” eCommerce shop for men. Bringing daily essentials to your doorstep.

B2BCHX – Background check a Chinese company. Easy due diligence. Prevent fraud or scams.

OfficeHop – A global sharing model platform for short term rentals of office and meeting rooms. (beta testing to begin end of 4^th quarter 2020)

Keep up to date on APPlife Digital Solutions events and developments join our online communities at Facebook, Twitter and LinkedIn. 

Contact Information:
APPlife Digital Solutions
Investor Relations
Tel: (585) 232-5440
Email: [email protected]

FORWARD-LOOKING STATEMENTS 

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects — both business and financial. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, acquisitions, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to APPlife Digital Solutions, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

SANTA MONICA, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — Leaf Group Ltd. (NYSE: LEAF), a diversified consumer internet company, today announced the appointment of Harold (Hal) Logan to the Company’s Board of Directors, effective November 20, 2020.

“Hal brings an extensive background in leading software and information businesses,” said Deborah Benton, Chair of the Leaf Group Board of Directors. “His unique insights and noteworthy leadership experiences will be critical as Leaf Group builds on its strong 2020 performance. Hal joins an already diverse Board in terms of background, skills, experience, as well as gender and ethnicity, which will be extremely valuable in continuing to drive shareholder value.”

Mr. Logan joins Leaf Group as a seasoned executive with over twenty years of senior management experience and a strong technology background. He currently serves on the Board of Directors for RepairPal, Inc. and Auction OS, and as Chairman Emeritus of the Board for Learning Ally. Mr. Logan previously served as Chief Executive Officer at BuyBook Technologies, Inc. prior to its acquisition by AutoTrader.com. He has also held executive roles at Manheim Auctions, Third Set Partners, Vicinity Corporation, Pacific Telesis Group, Dow Jones & Company and the Washington Post Company. Mr. Logan earned his MBA from Stanford University and holds a BA in economics from Harvard University.

“I am thrilled to be joining Leaf Group at such an important point for its growing business,” said Mr. Logan. “I look forward to working with my fellow Board members to help the Company extend its strong momentum and ensure it continues to make the most of the fundamental shifts in consumer behavior we are seeing today.”

About Leaf Group

Leaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness and wellness (Well+Good, Livestrong.com and MyPlate App), and home, art and design (Saatchi Art, Society6 and Hunker). For more information about Leaf Group, visit www.leafgroup.com.

Investor Contact

Shawn Milne
SVP Corporate Finance & Investor Relations
310-656-6346
[email protected]

Media Contact
s

John Christiansen/Matt Reid
Sard Verbinnen & Co
415-618-8750/310-201-2040
[email protected]

Sharna Daduk
VP, Communications
310-917-6405
[email protected]

SACRAMENTO, CA, Nov. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Today BrewBilt Manufacturing Inc. (the “Company”) (OTCPINK: BBRW), announced that the company filed an 8-K today disclosing that it repurchased 70,025,000 common shares at a price of $.002 in value of $140,000. The shares have been returned to treasury. On November 13, 2020 the company filed its Form-10Q ending September 30, 2020 with approximately $1M in sales, up from $500,000 in 2019 for the same period; with more than $700,000 net profit up from $100,000 in 2019. The company is showing gains of 5X, while reducing liabilities in the amount of $100,000 compared to 2019.

Jef Lewis, CEO, stated, “The Company repurchased 70,025,000 common shares and returned them to treasury on November 20, 2020. This represents more than 3% of our issued and outstanding shares. We anticipate a successful share buy-back considering the trajectory of our revenue for 2021. At the moment our projected buy-back of $5M represents more than our market capitalization of $4.2M, which may allow the Company to push the stock price up while repurchasing the shares.”

The company launched a new advertising campaign this quarter with multiple major trade media, inclusive of Food & Beverage and Pizza Today print and digital media. The first ads were released in October and as a result the company received $1.2M in quotes from restaurants that want to brew beer to increase their net profits and offer their own brand. “Quotes turn into real purchase orders which result in more revenue. This is part of a multifaceted strategy to build revenues in the USA, Europe and Asia. Currently with $3M in orders, and $15M in quotes from customers waiting for COVID to pass, realizes our projected 2021 revenue of $20M,” stated Jef Lewis, CEO. 

Watch Video Success Stories:

https://www.brewbilt.com/success-stories

https://www.youtube.com/watch?reload=9&v=eAtMrDj7PYA&feature=youtu.be

ABOUT BREWBILT:  (www.brewbilt.com)

Located in the Sierra Foothills of Northern California, BrewBilt is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation and distillation processing systems for the craft beer, cannabis and hemp industries using “Best in Class” American made components integrated with stainless steel processing vessels using only American made steel. Founded in 2014, the company began in a backyard shop by Jef Lewis with a vision of creating a profitable company in “Rural America”. BrewBilt has built a solid foundation by having strong relationships with local suppliers of raw materials, equipment and services in California, an aggressive referral network of satisfied customers nationwide, and an Advisory Board consisting of successful business leaders that provide valuable product feedback and business expertise to management. The craft brewing & spirits industries continue to grow worldwide. California is where craft brewing began and now has over 900 operating breweries – being centrally located in this booming market was a large draw for BrewBilt to locate its manufacturing facility in the Sierra foothills. All BrewBilt products are designed and fabricated as “food grade” quality which enables the company to build vessels for food & beverage processing. More important, the company has been building systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential much greater. 

FORWARD-LOOKING STATEMENTS This document contains forward-looking statements.  Forward-looking statements provide current expectations or forecasts of future events and are not guarantees of future performance, nor should they be relied upon as representing management’s views as of any subsequent date.  The forward-looking statements are based on management’s expectations and are subject to a number of risks and uncertainties.  Although management believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ materially from those expressed or implied in such statements.  Risks and uncertainties that could cause actual results to differ materially include, without limitation, the Corporation’s ability to effectively execute its business plans; changes in general economic and financial market conditions; changes in interest rates; changes in the competitive environment; continuing consolidation in the financial services industry; new litigation or changes in existing litigation; losses, customer bankruptcy, claims and assessments; changes in banking regulations or other regulatory or legislative requirements affecting the Corporation’s business; and changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other regulatory agencies.  Management may elect to update forward-looking statements at some future point; however, it specifically disclaims any obligation to do so.

Contact:

Jef Lewis, Chairman and CEO 
BrewBilt Manufacturing Inc. –  BBRW 
Call or Text: 530-802-5023
[email protected]

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) — The science of brain plasticity — and its ability to keep brain’s functioning at high levels throughout life — is the subject of a new documentary program for public television, entitled “The Brain Revolution,” which will begin airing nationwide on November 28^th. The program is the ninth public television documentary based on the groundbreaking work of Dr. Michael Merzenich, who is the co-founder of Posit Science, which makes the BrainHQ app for monitoring and improving cognitive abilities.

The program will delve into Dr. Merzenich’s lifelong study of how to achieve and maintain a healthy and high performing brain. This documentary was developed with funding from PBS as special programming for public television’s pledge drives, and generous donors will receive a copy of Dr. Merzenich’s book Soft-Wired: How the New Science of Brain Plasticity Can Change Your Life, as well as an annual subscription to BrainHQ, and a DVD library of prior brain fitness specials.

Posit Science and Dr. Merzenich began working with public television 12 years ago. At that time, their first such special, “The Brain Fitness Program,” became the most successful fundraiser in public television history.

“We are honored by the opportunity to support public television,” said Dr. Henry Mahncke, CEO of Posit Science. “We share a mission of providing everyone with access to tools that can improve the mind and enrich human experience. While I grew up with Sesame Street and Mister Rogers, these days I’m thankful that my entire family is nourished by programming that includes Masterpiece, Sherlock, Washington Week, the Great British Baking Show and, of course, Nova.”

Hosted by Ashleigh Banfield, the new documentary delves into the latest discoveries about improving brain function — through interviews with Dr. Merzenich and other noted experts, including Dr. Arthur Toga at USC, Dr. Jerri Edwards at USF, and Dr. Richard Frackowiak at the University of Lausanne.

Dr. Merzenich is credited with the seminal experiments that showed the brain is “plastic” – capable of chemical, physical and functional change – throughout life. Prior to his work, scientists believed the brain was only plastic during the development stage of childhood and then was destined to wear out over time. His work showing the brain remains plastic overturned existing models about how the brain works and began a still unfolding revolution in our understanding of the brain.

Dr. Merzenich was also the first to harness plasticity for human benefit through his co-invention of the cochlear implant — which engaged the brain’s plasticity with new machine-made electrical inputs from sound waves — to restore hearing to hundreds of thousands of people.

Dr. Merzenich then pioneered how computers might be used to measure brain function, deliver the right stimuli in brain exercises, and drive the brain in a positive direction.

That ongoing work resulted in the creation of the brain exercises and assessments found in BrainHQ — shown to deliver benefits in more than 200 published studies. Across varied populations, those exercises have driven gains in standard measures of cognition (e.g., speed, attention, memory, decision-making), in standard measures of quality of life (e.g., mood, confidence, health-related quality of life), and in real-world activities (e.g, balance, driving, work, maintaining independent living).

For his body of work, Dr. Merzenich has been honored by each of the US National Academies (Sciences, Medicine, and Engineering), and has been made a Kavli Laureate in Neuroscience, which is often described as the highest honor in his field.

Dr. Merzenich brought together hundreds of university-based scientists to help design, test, refine and validate the exercises and assessments in BrainHQ, and, on a daily basis at Posit Science, he oversees ongoing science and research efforts – including more nearly 300 more studies now in progress.

While best known among researchers for his admonitions to do “more, faster,” his advice to everyone else is to be mindful of the power and opportunity of lifelong plasticity.

 “Your brain – every brain – is a work in progress,” Dr. Merzenich notably observed. “It is ‘plastic.’ From the day we are born until the day we die. It continuously revises and remodels, improving or slowly declining, as a function of how we use it.” 

CHARLOTTE, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) — Extended Stay America, Inc. and ESH Hospitality, Inc. (NASDAQ:STAY) (together, the “Company”) today announced the completed disposition of one hotel in California for gross proceeds of $65.0 million. The hotel is now closed and the buyer expects to convert the hotel to an alternative use in the coming months.

The gross proceeds represent:

• 
  $445,200 per key valuation
  
• 
  20.2 times 2019 Property Adjusted EBITDA and 38.1 times trailing twelve month (“TTM”) Property Adjusted EBITDA as of September 30, 2020
  
• 
  Cap rate of 3.8% on 2019 Property Adjusted EBITDA and cap rate of 1.8% on TTM Adjusted EBITDA as of September 30, 2020
  

Extended Stay America’s President and Chief Executive Officer Bruce Haase, commented, “This sale highlights the strong intrinsic value of our large, geographically diverse real estate portfolio.   With the pace of development since the Company’s founding, it is impossible to replicate our real estate portfolio today.  We believe that our strategy to strategically curate our REIT assets at significantly accretive multiples, as evidenced by this transaction, will create significant shareholder value in the coming years.”

Distribution Update

The Company expects to generate taxable income on this asset sale of approximately $0.11 to $0.12 per ESH Hospitality, Inc. common share outstanding. The Company expects to distribute most or all the taxable income from the disposition to shareholders at the same time as its 2020 catch-up dividend in the first quarter of 2021, subject to Board approval.

Disclosure Regarding Non-GAAP Financial Measures

Property Adjusted EBITDA is used by the Company as a supplemental performance measure. The Company believes this measure provides useful information to investors regarding our results of operations and allow investors to evaluate the ongoing operating performance of our hotels and facilitate comparisons between the Company and other lodging companies, hotel owners and capital-intensive companies, including those which include a REIT as part of their legal entity structure. Property Adjusted EBITDA is not a recognized term under U.S. GAAP and it may not be comparable to similarly titled measures calculated by other companies. This measure should not be considered as alternative measure of, or superior to, operating profit, net income, net income per share or any other measure of the Company, Extended Stay America, Inc. or ESH Hospitality, Inc. calculated in accordance with U.S. GAAP.  The Company’s presentation of Property Adjusted EBITDA does not replace the presentation of the Company’s consolidated financial statements and other disclosures prepared in accordance with U.S. GAAP.  

Forward Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to, statements related to our expectations regarding our business performance, financial results, liquidity and capital resources, distribution policy, plans, goals, beliefs, business trends and future events, as well as the impact of the COVID-19 pandemic, its effects on the foregoing, government actions taken in response to the pandemic and actions that we have or plan to take in response to the pandemic and other non-historical statements. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results or performance to differ from those projected in the forward-looking statements, possibly materially. For a description of factors that may cause the Company’s actual results or performance to differ from projected results or performance implied by forward-looking statements, please review the information under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” included in the Company’s combined annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 26, 2020 and other documents of the Company on file with or furnished to the SEC, including the Company’s combined quarterly report on Form 10-Q filed on November 9, 2020. Any forward-looking statements made in this release are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, will have the expected consequences to, or effects on, the Company, its business or operations.  Except as required by law, the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. We caution you that actual results may differ materially from what is expressed, implied or forecasted by the Company’s forward-looking statements.

About Extended Stay America

Extended Stay America® is the leading brand in the mid-priced extended stay segment in the U.S. with 646 hotels.  ESH Hospitality, Inc. (“ESH”), a subsidiary of Extended Stay America, Inc. (“ESA”), is the largest lodging REIT in North America by unit and room count, with 563 hotels and over 63,000 rooms in the U.S. ESA also manages or franchises an additional 83 Extended Stay America® hotels. Visit www.esa.com for more information.

Contacts

Investors or Media:

Rob Ballew
(980) 345-1546
[email protected]

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO).

Over time the two companies plan to focus on Voltron’s VaxCelerate vaccine platform’s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication/patient population selection, trial site selection and supporting Voltron’s initial BLA submission.

“Voltron is excited to have forged a relationship with TD2 to best leverage and develop our novel vaccine platform, VaxCelerate. We believe TD2’s wide ranging expertise in oncology, from trial design and execution to regulatory strategy across all cancer types, will help Voltron create differentiating data to bring more effective treatments to market in less time. Our highly experienced operations team was instrumental in the selection process and was extremely impressed with TD2’s capabilities, track record and responsiveness. Our initial project will focus on VaxCelerate in the ovarian cancer setting with additional consideration being given to potential future opportunities in NSCLC, pancreatic cancer, head and neck cancer and mesothelioma,” said Pat Gallagher, Managing Partner at LVP and CEO of Voltron.

“TD2 is honored to be selected to work with the great team at Voltron to accelerate this novel self-assembling vaccine medicine to help patients with ovarian and other cancers,” said Stephen Gately, CEO at TD2. “We look forward to deploying our full translational oncology service offerings to support all needed aspects of development with a key focus on the clinical and regulatory strategy to select patients most likely to gain clinical benefit.”

“It continues to be an exciting time of growth for Laidlaw Venture Partners, and in particular, our portfolio company Voltron Therapeutics. In past months, we have announced the addition of numerous world class healthcare professionals to our team. Today’s Voltron news is a result of leveraging that team’s experience, varied skill sets and invaluable relationships forged over decades of specialized work in the medical field,” said James Ahern, Founding Partner, Laidlaw Venture Partners.

About Laidlaw & Company

Laidlaw & Company is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private institutions, public institutions, and high net worth individual investors.

Laidlaw & Company (U.K.) Ltd., a broker-dealer registered with FINRA in the United States, clears on a fully disclosed basis through INTL FC Stone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited, an affiliate of Laidlaw & Company, is authorized by the Financial Conduct Authority (FCA) in the United Kingdom.

Laidlaw Wealth Management is an affiliate of, and Laidlaw Venture Partners is a DBA, of Laidlaw & Company. For more information, please visit: https://laidlawltd.com/

About Translational Drug Development (TD2)

TD2 is an oncology development company that provides innovative services for oncology-focused organizations. Using a dedicated team of professionals with broad experience and understanding in oncology drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncologic diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, and clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new medicine, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Investor Contacts:

Matt Duffy, Managing Partner
646-335-5923
[email protected] 

Jason Assad
Investor Relations
678-570-6791
[email protected]